Controlled-release ketoprofen in rheumatoid arthritis and osteoarthritis: comparison of two doses in Thailand.

Thirty-one hospital outpatients in Thailand, 14 with rheumatoid arthritis and 17 with osteoarthritis, received 100 mg (15 patients) or 200 mg (16 patients) of controlled-release ketoprofen daily for 12 weeks. At the start of treatment, at day 42, and at day 84 (end of treatment) the patients were assessed for pain, duration and severity of morning stiffness, duration of daytime inactivity needed to produce stiffness, the duration of that stiffness, and overall clinical state. Blood and urine samples were taken to monitor hematological, renal, and carbohydrate function.